NYSE:BMYPharmaceuticals
The Bull Case For Bristol-Myers Squibb (BMY) Could Change Following Real-World Camzyos Data at ESC 2025
In late August 2025, Bristol Myers Squibb presented real-world data from the COLLIGO-HCM study at the European Society of Cardiology Congress, showing Camzyos (mavacamten) reduced left ventricular outflow tract obstruction and improved symptoms in diverse patients with symptomatic obstructive hypertrophic cardiomyopathy across seven countries.
The findings validated Camzyos' effectiveness and safety in real-world settings and reinforced its position as a standard of care, supporting its...